The EPS projection of Core Laboratories N.V. (NYSE:CLB) for period quarter completed 2016-12-31 is $0.42.
The EPS estimates given a week and 30-days ago were $0.42 and $0.42 correspondingly. This number 60 and 90 days before was $0.42 and $0.42 respectively. However, over last week ago, the change in EPS estimate is 0.01%.
For the quarter completed 2 mean estimate is $0.42 based on 4 EPS estimations. As on 2016-07-20 estimated EPS stood at $0.35 showing surprise of $0, or 0%. Following the disclosed forecasts, the standard deviation is $0.01.
The upgrade in EPS revisions were 0 a week earlier against negative revisions of 0. In last 1- month and 60-days, the upgrade in EPS revisions were 0 and 0 correspondingly, whereas for a quarter and 120-days earlier, it was 3 and 3 in that sequence.
The negative revisions of earnings per-share in the last 1-month and 60-days were 1 and 1 in that order. However, a quarter and 120-days earlier, this count was 0 and 0 correspondingly.
EPS revisions downgrade and upgrade in the last 18 days were 1 and 1, correspondingly.
Quarterly Sales Estimates
The arithmetic mean of apparent annual sales of Core Laboratories N.V. (NYSE:CLB) is $170.066 and the median is $167.3. The estimate is stated by 3 analysts for the fiscal 2017.
The highest yearly projection is $182.9 and lowest sales mark is $160. This results a standard deviation of $11.698.
Almost 3 have revised sales target positively in the past week and 3 have downgraded forecasts. Depending on the stated estimates, the calculated change in target against the past week is 3.92%.
Nearly 3 revised sales projections positively over the past month and 3 have downgraded forecasts. It leads to a mean estimate deviation of 3.92%.
Just about 3 have revised sales forecast positively over the quarter and 3 have downgraded forecasts, giving a deviation of 6.224%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...